global markets for infectious disease treatments

ReportLinker Find Industry reports, Company profilesand Market Statistics

>> Get this Report Now by email!

Global Markets for Infectious Disease Treatments

Published on May 2013

Report Summary

STUDY GOALS AND OBJECTIVES

Infectious diseases are one of the major causes of global morbidity and mortality. Viral, bacterial, parasitic and fungal diseases have

plagued humankind for centuries, and our attempts to control these diseases have met with great success. Diseases that were once

death sentences are now chronic and manageable diseases.

But as with every ongoing story, microbes have transformed themselves to outwit current medications, and the battle to rid humans of

the most virulent of diseases continues. With the constant combining and reinvention of microbes comes an urgent need for

improved antibiotic and viral medications to sustain the progress made in addressing the most aggressive of infectious diseases.

Under these circumstances, there is need for a current and comprehensive report on infectious diseases covering diagnosis,

treatment, demand trends, opportunities, and emerging technologies.

This study gives a clear, quantitative picture of the supply-and-demand scenario, and it highlights the technological and investment

opportunities in the field.

REASONS FOR DOING THE STUDY

This report provides the reader with a detailed analysis of the global infectious disease market, with emphasis on seven major

infectious diseases (i.e., human immunodeficiency virus/acquired immunodeficiency virus [HIV/AIDS]; hepatitis A, B, C; malaria,

rotavirus/diarrhea; measles; pneumonia; and tuberculosis [TB]).

The report also discusses technological developments, future trends, and emerging opportunities. The major objectives of this study

are:

' Assessing the current state of infectious diseases on a global basis.

' Identifying the driving factors for demand of new diagnostic and pharmaceutical products.

' Estimating current and future market sizes for diagnostic and pharmaceutical infectious disease products.

' Estimating the current global supply-and-demand scenario, by disease type and geographical regions.

' Identifying factors that influence the industry and proposing market opportunities.

SCOPE OF REPORT

The market report organizes information from diverse sources into a cohesive unit that includes an overview, global implications of

infectious diseases, infectious diseases by type, treatment and prevention, emerging pharmaceutical and diagnostic products, and an

applicable patents section. Information is organized by type of infectious disease (i.e., bacterial, viral, parasitic) and appropriate

treatments, both current and anticipated.

INTENDED AUDIENCE

Global Markets for Infectious Disease Treatments (From Issuu) /21

http://www.reportlinker.com?utm_campaign=plp&utm_source=issuu&utm_medium=referral



http://www.reportlinker.com/p01187982/Global-Markets-for-Infectious-Disease-Treatments.html#utm_campaign=plp&utm_source=issuu&utm_medium=referral




This updated version on the infectious disease market and technologies will be a valuable tool for decision makers and manufacturers

in both the diagnostic and the pharmaceutical treatment industries. Individuals at research foundations, manufacturing companies,

and university laboratories will find valuable information on the global diagnostic product and pharmaceutical industries. This

information will also be useful for individuals involved in strategic planning and marketing and sales development.

The audience will obtain a broad view of the social and economic consequences of infectious diseases. Additionally, emphasis on the

type of disease, major players in the marketplace, market conditions, and current and projected revenues will be provided.

METHODOLOGIES AND INFORMATION SOURCES

The data for this report were gathered from primary and secondary sources. Sources include information obtained from industry

analysis, manufacturers, academic and trade journals, and industry associations. Additional sources include the U.S. Patent and

Trademark Office (USPTO), U.S. Securities and Exchange Commission (SEC) filings, the World Health Organization (WHO), the

Centers for Disease Control (CDC), the Mayo Clinic, the Pharmaceutical Research and Manufacturing Association, and UNAIDS.

Where precise information was not available, a projection was made using reasonable assumptions and estimates based on historical

data. All market data are based on manufacturers' sales.

ANALYST CREDENTIALS

Peggy Lehr is the BCC Research analyst for this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder,

and an MS in Communication from the University of Denver. Ms. Lehr has worked as a researcher, editor, and publisher within the

publishing industry for both for-profit and not-for-profit organizations. She is the author of several BCC reports dealing with healthcare,

pharmaceuticals, and agriculture.

REPORT HIGHLIGHTS

This report provides:

' An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical

treatments, vaccines, and environmental products

' Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs)

through 2017

' Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans

' Examination of technological developments, future trends, and emerging opportunities

' Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral,

parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region

' Patent analysis

' Comprehensive company profiles of major players.

Table of Content

TABLE OF CONTENTS









CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2

REASONS FOR DOING THE STUDY 2

SCOPE OF REPORT 2

INTENDED AUDIENCE 3

METHODOLOGIES AND INFORMATION SOURCES 3

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ON-LINE SERVICES 4

DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE PROJECTED MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC,

VACCINE AND PHARMACEUTICAL PRODUCTS BY TYPE, THROUGH 2017 ($ MILLIONS) 7

SUMMARY FIGURE PERCENTAGE OF MARKET SHARE FOR INFECTIOUS DISEASE

DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY GEOGRAPHIC

REGION, 2012 AND 2017 (%)

8

CHAPTER 3 OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES, AND TREATMENT 10

TOP GLOBAL CAUSES OF DEATH 10

TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME

LEVEL (%) 11

MAJOR INFECTIOUS DISEASES 11

TABLE 2 SELECTED MAJOR INFECTIOUS DISEASES, WORLDWIDE, 2011 (NUMBER

OF CASES, TREATMENT OPTIONS) 11

HISTORICAL IMPACT OF INFECTIOUS DISEASES 12

LEADING CAUSES OF GLOBAL DEATHS 13

Transmission of Infectious Diseases 13

LINKING INFECTIOUS DISEASE TO CANCER 13

TREATMENTS FOR INFECTIOUS DISEASES 13

PREVENTION 13

VACCINATION 14

FIGURE 1 VACCINE-PREVENTABLE DEATHS IN CHILDREN UNDER FIVE YEARS OF

AGE, 2008 (THOUSANDS) 14

TABLE 3 VACCINE-PREVENTABLE DISEASE DEATHS IN CHILDREN UNDER 5 YEARS

OF AGE BY REGION, 2008 (000) 15

GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET 15

TYPES OF DIAGNOSTIC TESTING 15

FLUORESCENT IMMUNOASSAY (FIA) 16

Direct Fluorescent Antibody Testing (FA) 16

Indirect Fluorescent Antibody Testing (IFA) 16

Chemiluminescent Microparticle Immunoassay (CIA) 16

ENZYME IMMUNOASSAY (EIA) 16

Basic EIA 17









Enzyme-Linked Immunosorbent Assay (ELISA) 17

GENE PROBE ANALYSIS 17

Polymerase Chain Reaction Amplification (PCR) 18

Nucleic Acid Amplification Test (NAT) 18

Transcription-Mediated Amplification (TMA) 18

Nucleic Acid Sequence-Based Amplification (NASBA) 19

GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 19

TABLE 4 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE

DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 19

GLOBAL INFECTIOUS DISEASE VACCINE MARKET 19

TABLE 5 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE

PRODUCTS, THROUGH 2017 ($ MILLIONS) 20

THE GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET 20


PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 20

PROJECTIONS FOR GLOBAL INFECTIOUS DISEASE PRODUCTS BY TYPE AND

DISEASE 21

TABLE 7 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC,

VACCINE AND TREATMENT PRODUCTS, THROUGH 2017 ($ MILLIONS) 21

VACCINE OPPORTUNITIES 22

CHILDHOOD DISEASES 22

GLOBAL HUMANITARIAN AGENCIES 22

PHARMACEUTICAL OPPORTUNITIES 23

THE EMERGENCE OF GENE THERAPY 23

MERGERS AND ACQUISITIONS 24

TABLE 8 SELECTED MERGERS AND ACQUISITIONS, 2008-2013 ($ MILLIONS) 24

CHAPTER 4 VACCINES-THE PRESENT AND THE FUTURE 26

MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES 26

TABLE 9 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES,

THROUGH 2017 ($ MILLIONS) 26

TYPES OF VACCINES 27

LIVE ATTENUATED VACCINE 27

INACTIVATED VACCINE 27

Acellular/Subunit Vaccines 27

IMMUNITY 27

INNATE IMMUNITY 28

ACQUIRED IMMUNITY 28

The Activity of T Cells 28

Acquired Immunity-Cell-Mediated Response 29

LASTING IMMUNITY 29

VIRAL DISEASES PREVENTED BY VACCINE 29

TABLE 10 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 29

BACTERIAL DISEASES PREVENTED BY VACCINE 30

TABLE 11 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 30

VACCINATION SCHEDULES FOR CHILDREN 30

TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS 31









TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS TO 4 TO 6

YEARS 31

TABLE 14 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7

TO 18 32

CONCERNS REGARDING VACCINATION IN CHILDHOOD 32

NUMBER OF INOCULATIONS 32

RECOGNIZING IMMUNE RESPONSE 32

IMMUNIZATION AND WEAKENED OR ALTERED IMMUNE SYSTEMS 33

VACCINE PRODUCTION 33

FIGURE 2 VACCINE MANUFACTURING PROCESS 33

VACCINE MANUFACTURERS 34

TOP- SELLING VACCINES OF 2011 35

TABLE 15 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION,

MANUFACTURER AND REVENUE, 2011 35

REGIONAL ANALYSIS 35

TABLE 16 PROJECTED REGIONAL MARKETS FOR VACCINES, THROUGH 2017 ($

MILLIONS) 35

FIGURE 3 PERCENTAGE OF MARKET SHARE FOR VACCINES BY REGION, 2012 AND

2017 36

THE AMERICAS 37

TABLE 17 PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY

REGION, THROUGH 2017 ($ MILLIONS) 37


DISEASE, THROUGH 2017 ($ MILLIONS) 38

EMRA 38

TABLE 19 PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,

BY REGION, THROUGH 2017 ($ MILLIONS) 38


BY DISEASE, THROUGH 2017 ($ MILLIONS) 39

ASIA 39

TABLE 21 PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,




TRENDS IN VACCINE DEVELOPMENT 40

COMBINATION VACCINES 40

INHALED OR INTRANASAL VACCINE ADMINISTRATION 40

CHAPTER 5 VIRAL INFECTIOUS DISEASES 43

GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND

PHARMACEUTICAL PRODUCTS 43

TABLE 23 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE

DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 43

HEPATITIS B AND C 43

TABLE 24 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND


RISK FACTORS 44









TREATMENTS 44

HERPES SIMPLEX VIRUS 45

TABLE 25 PROJECTED GLOBAL MARKET FOR HSV DIAGNOSTIC AND


INCIDENCE 45

DIAGNOSIS 46

TABLE 26 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPES

BY BRAND NAME, TYPE AND MANUFACTURER, 2012 46

TREATMENT 47

TABLE 27 MEDICATIONS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME

AND MANUFACTURER 47

HEPATITIS B AND C 48

TABLE 28 PROJECTED GLOBAL MARKET FOR HEPATITIS B AND C DIAGNOSTIC AND


DIAGNOSIS 48

TABLE 29 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET SHARE BY TYPE OF

TEST AND REVENUES, 2011 ($ MILLIONS/%) 48

TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND

C BY BRAND NAME AND MANUFACTURER, 2012 49

Automated Infectious Disease Testing for Hepatitis 50

TREATMENT MARKET 50

TABLE 31 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING,

BY REVENUES, 2011 ($ MILLIONS) 51

FIGURE 4 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET

AND THEIR MARKET SHARE, 2011 (%) 51

TABLE 32 MEDICATIONS FOR THE TREATMENT OF HEPATITIS B AND C, 2012 52

HIV/AIDS 52

TABLE 33 PROJECTED GLOBAL MARKET FOR HIV DIAGNOSTIC AND


RISK FACTORS 53

INCIDENCE/MORTALITY 54

HAART TREATMENT 54

HAART Failure 55

Mega-HAART 55

HIV TREATMENT FOR INFANTS 55

HUMAN PAPILLOMAVIRUS 55

HPV AND CANCER 55

INCIDENCE 56

SYMPTOMS 56

DIAGNOSIS 56

TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND

NAME, TYPE AND MANUFACTURER, 2012 57

TREATMENT 57

TABLE 35 MEDICATIONS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME,

AND MANUFACTURER 57

INFLUENZA A AND B 57

VACCINE 58

TREATMENT 58









MEASLES 58

PNEUMONIA 58

BACTERIAL PNEUMONIA 58

Vaccine 59

Treatment 59

VIRAL PNEUMONIA 59

Treatment 59

ROTAVIRUS 59

DEHYDRATION 60

ZINC 60

RSV 60

SYMPTOMS 60

DIAGNOSTIC PRODUCTS 61

TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND

TYPE 2012 61

VIRAL DIAGNOSTIC PRODUCTS 61



VIRAL PHARMACEUTICAL PRODUCTS 62





DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($

MILLIONS)

63

FIGURE 5 PERCENTAGE OF THE GLOBAL VIRAL DIAGNOSTIC AND

PHARMACEUTICAL MARKETS BY REGIONS, 2012 AND 2017 (%) 63

TABLE 40 PROJECTED MARKET FOR VIRAL DIAGNOSTIC PRODUCTS BY REGION,


TABLE 41 PROJECTED MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS BY


AMERICAS 65

Hepatitis B in the U.S. 65

Hepatitis C in the U.S. 66

Hepatitis in Canada 66

Market for Viral Infectious Disease Products in the Americas 66

TABLE 42 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE

DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 66


PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 67

Americas Diagnostic and Pharmaceutical Products Market, by

Disease 67

TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC

AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($ MILLIONS) 67

EMRA 67

Hepatitis B, C in EMRA 67

Hepatitis in Africa 68









Hepatitis in Russia, Eurasia 68

Market for Viral Infectious Disease Diagnostic and Pharmaceutical

Products 68

TABLE 45 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC

PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 68

TABLE 46 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE


EMRA Market for Infectious Disease Diagnostic and Pharmaceutical

Products, by Disease 69

TABLE 47 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND

PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($ MILLIONS) 70

ASIA 70

Hepatitis in Asian Region 70

Hepatitis in Japan 70

Hepatitis in China 70

Hepatitis in India 71

TABLE 48 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE


TABLE 49 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE


TABLE 50 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND


CHAPTER 6 BACTERIAL INFECTIOUS DISEASES AND THE SPECTER OF ANTIBIOTIC

RESISTANCE 74

NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES 74

TABLE 51 NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES 74

MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND

PHARMACEUTICAL PRODUCTS 74

TABLE 52 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES

DIAGNOSTIC AND TREATMENT PRODUCTS, THROUGH 2017 ($ MILLIONS) 75

MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTICS 75


DIAGNOSTICS, THROUGH 2017 ($ MILLIONS) 75

MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS 76


PHARMACEUTICALS, THROUGH 2017 ($ MILLIONS) 76

NOTABLE BACTERIAL DISEASES 76

CORYNEBACTERIUM DIPHTHERIAE, CLOSTRIDIUM TETANI, BORDETELLA

PERTUSSIS 76

Diphtheria 76

Tetanus 77

Pertussis 77

MENINGITIS 77

MYCOBACTERIUM TUBERCULOSIS (TB) 78

TABLE 55 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC AND

PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 78









EPIDEMIOLOGY OF TB 78

GEOGRAPHIC PREVALENCE 79

TABLE 56 PROJECTED MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL

PRODUCTS, BY REGION, THROUGH 2017 ($ MILLIONS) 79

FINANCING CONTROL EFFORTS 80

ANTIBIOTIC DEVELOPMENT 80

TABLE 57 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL 80

TABLE 58 ANTIBIOTIC CLASSES AND THEIR MODE OF ACTION 81

ANTIBIOTIC RESISTANCE 81

MECHANISMS OF RESISTANCE 82

METHODS OF RESISTANCE 83

Beta-Lactamase Production 83

Importing Resistance from Other Organisms 83

Examples of Antibiotic-Resistant Bacteria 84

Alteration of Binding Sites to Circumvent Anti-Infective Effectiveness 84

Antibiotic Discharge 84

PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE 85

FAILURE TO FINISH ANTIBIOTIC COURSES 85

ANTIBIOTIC OVERUSE 85

AGRICULTURAL PRACTICES 85

TABLE 59 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS IN

2009, BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL (POUNDS/%) 86

PATIENT PRESSURE 86

INTERNATIONAL SURVEILLANCE OF ANTIBIOTIC-RESISTANT ORGANISMS 87

RESISTANCE BY CLASS OF ANTIBIOTIC 87

TABLE 60 ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED 87

INCIDENCES OF ANTIBIOTIC RESISTANCE 87

ANTIBIOTIC RESISTANCE IN EUROPE 87

ANTIBIOTIC RESISTANCE IN THE U.S. 88

MAJOR ANTIBIOTIC-RESISTANT ORGANISMS 88

VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) 88

METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 88

CLOSTRIDIUM DIFFICILE (C. DIFFICILE) 89


TABLE 61 PROJECTED GLOBAL MARKET FOR BACTERIAL DIAGNOSTIC AND


FIGURE 6 MARKET SHARE OF BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND

PHARMACEUTICAL PRODUCTS BY REGION, 2012 AND 2017 (%) 89

THE AMERICAS 90

TABLE 62 PROJECTED AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND

PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 91

Bacterial Infection Diagnostic Product Market in the Americas 91

TABLE 63 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN

THE AMERICAS BY REGION, THROUGH 2017 ($ MILLIONS) 91

Bacterial Infection Pharmaceutical Market in the Americas 91

TABLE 64 BACTERIAL INFECTION PHARMACEUTICAL PRODUCT MARKET IN THE

AMERICAS, BY REGION, THROUGH 2017 ($ MILLIONS) 91

Americas Bacterial Infectious Diseases Diagnostic and









Pharmaceutical Market, by Disease 92

TABLE 65 PROJECTED AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASES

DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($

MILLIONS)

92

EMRA 93

TABLE 66 PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES


Bacterial Infectious Diseases Diagnostic Market in EMRA 93


EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 94

Bacterial Infectious Diseases Pharmaceutical Product Market in EMRA 94

TABLE 68 BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET

IN EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 94

EMRA Bacterial Infectious Diseases Diagnostic and Pharmaceutical

Market, by Disease 94

TABLE 69 PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES

DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY DISEASE, THROUGH 2017 ($

MILLIONS)

94

ASIA 95

TABLE 70 PROJECTED ASIA MARKET FOR BACTERIAL INFECTIOUS DISEASES

DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 96

Bacterial Infectious Diseases Diagnostic Product Market in Asia 96


ASIA BY REGION, THROUGH 2017 ($ MILLIONS) 96

Bacterial Infectious Diseases Pharmaceutical Product Market in Asia 97

TABLE 72 BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET

IN ASIA, BY REGION, THROUGH 2017 ($ MILLIONS) 97

Asian Bacterial Infectious Diseases Diagnostic and Pharmaceutical

Market, by Disease 97

TABLE 73 PROJECTED ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES

DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($

MILLIONS)

97

CHAPTER 7 PARASITIC INFECTIOUS DISEASES 99

NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES 99

TABLE 74 NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES 99

CLIMATE CHANGE AND VECTOR-BORNE DISEASES 99

MALARIA 100

INCIDENCES OF MALARIA 100

TABLE 75 ESTIMATED 2010 GLOBAL MALARIA CASES AND ESTIMATED DEATHS,

RATE OF DECREASE OF MALARIA DEATHS SINCE 2000, BY REGION* 101

CAUSES OF MALARIA 101

SYMPTOMS OF MALARIA 101

GLOBAL MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC AND









PHARMACEUTICAL TREATMENTS 101

TABLE 76 PROJECTED GLOBAL MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC

AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 102

INTERVENTIONAL TECHNIQUES TO MINIMIZE EXPOSURE TO MALARIAL

VECTORS 102

TABLE 77 PROJECTED GLOBAL MARKET FOR INSECTICIDE-TREATED NETS,


DIAGNOSIS OF MALARIA 103

TABLE 78 PROJECTED GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS,


TREATMENT OF MALARIA 103

TABLE 79 CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH

TREATMENT AND MANUFACTURER, 2012 104

TABLE 80 PROJECTED GLOBAL MARKET FOR MALARIAL DRUG TREATMENTS,




TABLE 81 PROJECTED GLOBAL MARKET FORMAL ARIAL PREVENTION, DIAGNOSTIC

AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 105

FIGURE 7 GLOBAL MARKET FOR MALARIAL TREATMENTS BY REGION 2012 AND

2017 (%) 105

THE AMERICAS 106

TABLE 82 PROJECTED AMERICAS MARKET FOR MALARIAL PREVENTION,

DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 107

Malarial Prevention Product Market in the Americas 107

TABLE 83 MALARIAL PREVENTION PRODUCT MARKET IN THE AMERICAS BY REGION,


Malarial Diagnostic Product Market in the Americas 107

TABLE 84 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION,


Malarial Pharmaceutical Market in the Americas 108

TABLE 85 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS BY


EMRA 108

TABLE 86 PROJECTED EMRA MARKET FOR MALARIAL PREVENTIVE, DIAGNOSTIC

AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 109

Malarial Prevention Market in the EMRA 109

TABLE 87 MALARIAL PREVENTIVE PRODUCT MARKET IN EMRA, BY REGION,


Malarial Diagnostic Product Market in EMRA 109

TABLE 88 MALARIAL DIAGNOSTIC PRODUCT MARKET IN EMRA, BY REGION,


Malarial Pharmaceutical Product Market in the EMRA 110

TABLE 89 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE EMRA, BY


ASIA 110

TABLE 90 PROJECTED ASIA MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC,

AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 111









TABLE 91 MALARIAL PREVENTION PRODUCT MARKET IN ASIA BY REGION,


TABLE 92 MALARIAL DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION,


TABLE 93 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN ASIA BY REGION,


TABLE 94 CURRENT ANT PARASITIC PHARMACEUTICALS WITH TRADENAME,

GENERIC NAME, MANUFACTURER, AND AREA OF TREATMENT, 2012 113

MARKET FOR ANTIPARASITIC PHARMACEUTICALS 113

CHAPTER 8 EMERGING TECHNOLOGY AND PHARMACEUTICALS 115

HEPATITIS C 115

POLYMERASE 115

Vertex Pharmaceuticals 115

NS5B 115

Roche 115

Boehringer Ingelheim 115

INFLUENZA 115

VAXINNATE 116

HSV 116

MALARIA 117

VACCINE 117

PHARMACEUTICALS 117

DIAGNOSTIC TESTING 117

ANTIBIOTIC RESISTANCE 118

GALAPAGOS NV 118

TRIUS THERAPEUTICS 118

CRESTONE PHARMA 119

BASILEA PHARMACEUTICA 119

POLYPHOR 119

REMPEX PHARMA 119

PHARMACEUTICAL TREATMENT PRODUCT PIPELINE 120

TABLE 95 INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY

DISEASE, 2012 120

CHAPTER 9 PATENT ANALYSIS 128

PHARMACEUTICAL PATENTS, BY PATENT NUMBER, DISEASE, COMPANY,

DESCRIPTION AND APPROVAL DATE 128

TABLE 96 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, BY

PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION AND APPROVAL

DATE, FEBRUARY 2006 TO FEBRUARY 2013

129

DIAGNOSTIC PATENTS ISSUED, BY COMPANY, APPROVAL DATE, AND DISEASE 141

TABLE 97 INFECTIOUS DISEASES DIAGNOSTIC PATENTS, BY PATENT NUMBER,

DISEASE, COMPANY, PRODUCT DESCRIPTION, AND APPROVAL DATE, MARCH

2005-DECEMBER 2012









142

PATENTS ISSUED BY COMPANY 142

TABLE 98 INFECTIOUS DISEASES PHARMACEUTICAL, VACCINE, AND DIAGNOSTIC

PRODUCT PATENTS BY COMPANY, MARCH 2005-FEBRUARY 2013 143

PATENTS ISSUED BY COUNTRY 144

TABLE 99 INFECTIOUS DISEASE PRODUCT DIAGNOSIS, VACCINE AND TREATMENT

PATENTS BY COUNTRY, JANUARY 2005 TO FEBRUARY 2013 (NUMBER/%) 145

FIGURE 8 NUMBER OF INFECTIOUS DISEASES PRODUCT DIAGNOSIS, VACCINE AND

TREATMENT PATENTS BY COUNTRY, JANUARY 2005-FEBRUARY 2013 (%) 146

INFECTIOUS DISEASES PATENTS ISSUED, BY DISEASE 146

TABLE 100 PATENTS ISSUED FOR DIAGNOSIS, VACCINE AND TREATMENT OF

INFECTIOUS DISEASES, BY DISEASE, MARCH 2005-FEBRUARY 2013 (NUMBER/%) 146

FIGURE 9 INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL

PATENTS BY DISEASE ISSUED BETWEEN MARCH 2005 AND DECEMBER 2012, (%) 147

INFECTIOUS DISEASES PATENTS, BY YEAR 147

TABLE 101 NUMBER OF INFECTIOUS DISEASES PATENTS FOR DIAGNOSTIC,

VACCINE AND PHARMACEUTICAL PRODUCTS, BY DISEASE AND YEAR, 2005-2013 148

CHAPTER 10 COMPANY PROFILES 150

ABBOTT LABORATORIES 150

BUSINESS OVERVIEW 150

PRODUCTS 150

TABLE 102 ABBOTT PHARMACEUTICAL PRODUCTS 150

DIAGNOSTIC PRODUCTS 151

TABLE 103 ABBOTT DIAGNOSTIC PRODUCTS 151

ALERE 151


PRODUCTS 152

TABLE 104 ALERE DIAGNOSTIC PRODUCTS 152

ALFA SCIENTIFIC DESIGNS 153


PRODUCTS 153

TABLE 105 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS 153

ATLAS LINK BIOTECH CO., LTD. 154


PRODUCTS 154

TABLE 106 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS 154

ASTRA ZENECA 155


PRODUCTS 155

TABLE 107 ASTRA ZENECA PHARMACEUTICAL PRODUCTS 155

BAXTER HEALTHCARE 155


PRODUCTS 156

TABLE 108 BAXTER PHARMACEUTICAL PRODUCTS 156

BAYER AG 156










PRODUCTS 156

TABLE 109 BAYER PHARMACEUTICAL PRODUCTS 156

BECTON DICKINSON 157


PRODUCTS 157

TABLE 110 BECTON DICKINSON DIAGNOSTIC PRODUCTS 157

BIO-RAD LABORATORIES 157


PRODUCTS 158

TABLE 111 BIORAD DIAGNOSTIC PRODUCTS 158

BOEHRINGER INGELHEIM GMBH 158


PRODUCTS 159

TABLE 112 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS 159

BRISTOL-MYERS SQUIBB COMPANY 159


PRODUCTS 159

TABLE 113 BRISTOL-MYERS SQUIBB PHARMACEUTICAL PRODUCTS 159

CEPHEID 160


PRODUCTS 160

TABLE 114 CEPHEID DIAGNOSTIC PRODUCTS 160

CRUCELL NV 160


PRODUCTS 161

TABLE 115 CRUCELL VACCINE PRODUCTS 161

CUBIST PHARMACEUTICALS 162


PRODUCTS 162

TABLE 116 CUBIST PHARMACEUTICAL PRODUCT 162

DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC. 162


PRODUCTS 163

TABLE 117 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC

PRODUCTS 163

DIASORIN 163


PRODUCTS 164

TABLE 118 DIAGNOSTIC PRODUCTS 164

ENANTA PHARMACEUTICALS 164


ENZO BIOCHEM 165


PRODUCTS 165

TABLE 119 ENZO BIOCHEM DIAGNOSTIC PRODUCTS 165

FIRST DIAGNOSTIC LLC 165


PRODUCTS 166









TABLE 120 FIRST DIAGNOSTIC PRODUCTS 166

GILEAD SCIENCES INC. 166


PRODUCTS 167

TABLE 121 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS 167

GLAXOSMITHKLINE 167


PRODUCTS 168

TABLE 122 GLAXOSMITHKLINE PHARMACEUTICAL/VACCINE PRODUCTS 168

HOLOGIC GEN-PROBE INC. 169


PRODUCTS 169

TABLE 123 HOLOGIC/GENPROBE DIAGNOSTIC PRODUCTS 169

HOME ACCESS HEALTH INC. 169


PRODUCTS 170

TABLE 124 HOME ACCESS DIAGNOSTIC PRODUCTS 170

IDENIX PHARMACEUTICALS 170


IMMUNOSTICS 170


PRODUCTS 171

TABLE 125 IMMUNOSTICS DIAGNOSTIC PRODUCTS 171

IND DIAGNOSTIC INC. 171


PRODUCTS 172

TABLE 126 IND DIAGNOSTIC PRODUCTS 172

INVERNESS MEDICAL INNOVATIONS (SEE ALERE) 172

IPCA LABORATORIES 172


JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS) 173


PRODUCTS 173

TABLE 127 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS 173

MANGALAM DRUGS & ORGANICS LTD. 173


MEDMIRA INC 174


PRODUCTS 174

TABLE 128 EDMIRA DIAGNOSTIC PRODUCTS 174

MERCK & COMPANY INC. 174


PRODUCTS 175

TABLE 129 MERCK VACCINE PRODUCTS 175

TABLE 130 MERCK PHARMACEUTICAL PRODUCTS 175

MERIDIAN BIOSCIENCE 176


PRODUCTS 176









TABLE 131 MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTS 176

NOVARTIS CORPORATION 177


PRODUCTS 178

TABLE 132 NOVARTIS DIAGNOSTIC PRODUCTS 178

TABLE 133 NOVARTIS PHARMACEUTICAL PRODUCTS 178

ORASURE TECHNOLOGIES INC. 178


PRODUCTS 179

TABLE 134 ORASURE DIAGNOSTIC PRODUCTS 179

ORTHO CLINICAL DIAGNOSTICS 179


PRODUCTS 179

TABLE 135 ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS 179

PARATEK PHARMACEUTICALS 180


PFIZER INC 180


PRODUCTS 181

TABLE 136 PFIZER VACCINE PRODUCTS 181

TABLE 137 PFIZER PHARMACEUTICAL PRODUCTS 181

PRINCETON BIOMEDITECH CORPORATION 181


PRODUCTS 182

TABLE 138 PRINCETON BIOMEDICTECH DIAGNOSTIC PRODUCTS 182

PROTEIN SCIENCES CORPORATION 182


QUIDEL 183


PRODUCTS 183

TABLE 139 QUIDEL DIAGNOSTIC PRODUCTS 183

QUIGEN N.V. 183


PRODUCTS 184

TABLE 140 QUIGEN DIAGNOSTIC PRODUCTS 184

ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.) 184


PRODUCTS 185

TABLE 141 ROCHE DIAGNOSTIC PRODUCTS 185

TABLE 142 ROCHE PHARMACEUTICAL PRODUCTS 185

RIB-X PHARMACEUTICALS 185


ROMARK LABORATORIES 186


SANOFI PASTEUR 186


PRODUCTS 187

TABLE 143 SANOFI PASTEUR PHARMACEUTICAL PRODUCTS 187









SCICLONE PHARMACEUTICALS 187


PRODUCTS 188

TABLE 144 SCICLONE PHARMACEUTICAL PRODUCTS 188

SHANGHAI KEHUA BIO-ENGINEERING CO., LTD. 188


PRODUCTS 188

TABLE 145 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS 188

STANDARD DIAGNOSTICS INC 189


PRODUCTS 189

TABLE 146 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS 189

TETRAPHASE PHARMACEUTICALS 190

TRINITY BIOTECH PLC 190


PRODUCTS 191

TABLE 147 TRINITY BIOTECH DIAGNOSTIC PRODUCTS 191

VERTEX PHARMACEUTICALS 191


PRODUCTS 192

TABLE 148 VERTEX PHARMACEUTICAL PRODUCTS 192

VIIV HEALTHCARE 192


PRODUCTS 193

TABLE 149 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS 193

LIST OF TABLES

SUMMARY TABLE PROJECTED MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC,

VACCINE AND PHARMACEUTICAL PRODUCTS BY TYPE, THROUGH 2017 ($ MILLIONS) 7

TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME

LEVEL (%) 11

TABLE 2 SELECTED MAJOR INFECTIOUS DISEASES, WORLDWIDE, 2011 (NUMBER OF

CASES, TREATMENT OPTIONS) 11

TABLE 3 VACCINE-PREVENTABLE DISEASE DEATHS IN CHILDREN UNDER 5 YEARS OF

AGE BY REGION, 2008 (000) 15



TABLE 5 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE

PRODUCTS, THROUGH 2017 ($ MILLIONS) 20



TABLE 7 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC,

VACCINE AND TREATMENT PRODUCTS, THROUGH 2017 ($ MILLIONS) 21

TABLE 8 SELECTED MERGERS AND ACQUISITIONS, 2008-2013 ($ MILLIONS) 24

TABLE 9 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES,










TABLE 10 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 29

TABLE 11 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 30

TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS 31

TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS TO 4 TO 6

YEARS 31

TABLE 14 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 TO

18 32

TABLE 15 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION,

MANUFACTURER AND REVENUE, 2011 35

TABLE 16 PROJECTED REGIONAL MARKETS FOR VACCINES, THROUGH 2017 ($

MILLIONS) 35




DISEASE, THROUGH 2017 ($ MILLIONS) 38











TABLE 24 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND


TABLE 25 PROJECTED GLOBAL MARKET FOR HSV DIAGNOSTIC AND


TABLE 26 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPES

BY BRAND NAME, TYPE AND MANUFACTURER, 2012 46

TABLE 27 MEDICATIONS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND

MANUFACTURER 47

TABLE 28 PROJECTED GLOBAL MARKET FOR HEPATITIS B AND C DIAGNOSTIC AND


TABLE 29 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET SHARE BY TYPE OF

TEST AND REVENUES, 2011 ($ MILLIONS/%) 48

TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C

BY BRAND NAME AND MANUFACTURER, 2012 49

TABLE 31 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING, BY

REVENUES, 2011 ($ MILLIONS) 51

TABLE 32 MEDICATIONS FOR THE TREATMENT OF HEPATITIS B AND C, 2012 52

TABLE 33 PROJECTED GLOBAL MARKET FOR HIV DIAGNOSTIC AND


TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND

NAME, TYPE AND MANUFACTURER, 2012 57

TABLE 35 MEDICATIONS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME,









AND MANUFACTURER 57

TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND

TYPE 2012 61






DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($

MILLIONS)

63

TABLE 40 PROJECTED MARKET FOR VIRAL DIAGNOSTIC PRODUCTS BY REGION,


TABLE 41 PROJECTED MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS BY REGION,






TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND


TABLE 45 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC

PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 68

TABLE 46 PROJECTE








>> Get this Report Now by email!Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require.

Product Formats Please select the product formats and the quantity you require.

Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________

Global Markets for Infectious Disease Treatments

1 User License--USD 5 450.00 Quantity: _____

Department License--USD 6 650.00 Quantity: _____

Corporate License--USD 9 350.00 Quantity: _____








>> Get this Report Now by email!Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel

RIB : 10278 07314 00020257701 89

BIC : CMCIFR2A

IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at

http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93

Customer signature:







global markets for infectious disease treatments

Documents

type of infectious disease

majorinfectious diseases

virulent of diseases

objectivesinfectious

manageable diseases

market opportunities

disease type

current global supply